CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
智能可调控 CAR-T 细胞疗法引领新趋势
英文原题：Intelligent tunable CAR-T cell therapy leads the new trend.
查看英文原题
Intelligent tunable CAR-T cell therapy leads the new trend.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
经工程化的嵌合抗原受体（CAR）T细胞过继输注已被证明可强效治疗血液系统恶性肿瘤。然而，CAR-T 治疗仍存在安全性和疗效方面的问题，包括细胞因子释放综合征（CRS）、T细胞耗竭和抗原逃逸。此外，由于CAR-T 细胞浸润不足、功能持续性差以及肿瘤微环境存在多种免疫抑制，CAR-T 治疗在实体瘤中的应用受到限制。为克服这些局限并拓展其适用范围，研究者开发了多种可控CAR-T 技术。本文综述智能可控CAR-T 技术的设计及其近年来带来的创新进展。
展开英文摘要原文
Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies.
However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still raised when patients are treated with CAR-T cells.
Moreover, CAR-T therapy has limited applications in treating solid tumors, owing to inefficient infiltration and poor functional persistence of CAR-T cells and diverse immunosuppression in tumor microenvironment. In order to overcome these limitations and broad its applications, multiple controllable CAR-T technologies were exploited. In this article, we review the designs of intelligent controlled CAR-T technologies and the innovations that they bring about in recent years.
论文信息
- 作者
- Cheng J、Liu M、Zhang J
- 文献类型
- 综述
- 期刊
- Synthetic and systems biotechnology2023 Dec
- 原文标识
- PubMed 37753197 · DOI 10.1016/j.synbio.2023.09.001
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →